Focus on the key players: Surveying the proteome with high-density antibody panels

Disease states may be caused by aberrant protein expression, modification, or interactions with other proteins. This network of protein interactions results in a unique molecular signature for that pathological state which can be mined for diagnostics, drug target discovery, or insights into the mechanism of that disease.

To find powerful sets of biomarkers, proteomic methods are heavily relied upon, particularly mass spectrometry-based methods and increasingly, affinity proteomics. The strategy of using a large, diverse, curated panel of antibodies (i.e., antibody array) to assess the composition of a biological sample allows the researcher to focus on markers with known relevance in key signaling pathways, while avoiding the pitfalls of ion suppression from irrelevant high abundance proteins

This webinar will describe how high-density antibody arrays are used to answer critical questions about diagnosis, molecular pathology, and mechanisms of drug resistance. Key findings of published studies on cancer and other complex diseases will also be presented.

Key learning objectives

In this webinar you will learn how high-density antibody arrays are used to:

• Classify disease sub-types
• Establish molecular pathology of a chronic disease
• Identify factors contributing to drug resistance

Who should attend?

Basic, pre-clinical and clinical researchers

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.